Phathom (PHAT) news
Recent news
Pathom Pharmaceuticals, - topline results from phase 3 study expected in Q1 2028
Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT) has announced that it expects to release top-line results from a Phase 3 clinical study in the first quarter of 2028. The study is part of the company’s ongoing efforts to evaluate the efficacy and safety of its gastrointestinal therapies. While specific…
AInvest Wire · Sep 29, 2026Phathom Pharmaceuticals - topline results from Phase 2 trial expected in Q4 2026
AInvest Wire · Jun 23, 2026Phathom shares paused for volatility
Phathom shares paused for volatility Phathom Pharmaceuticals, Inc. (NASDAQ: PHAT), a biopharmaceutical company specializing in gastrointestinal disease treatments, saw its stock price experience a slight dip of 0.25% on June 6, 2025, trading at $4.70. This volatility is part of the broader market…
AInvest Wire · Jun 6, 2025Light Horse does not author, endorse or verify the headlines, and their appearance here is not an endorsement of any view they express.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.